Edward Owens buys Cubist Pharmaceuticals Inc., adds to Cephalon Inc., Johnson & Johnson, Onyx Pharmaceuticals Inc. and sells Mead Johnson Nutrition, Gilead Sciences Inc., Allergan Inc. during the 3-months ended 09/30/2009, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $18.2 billion. These are the details of the buys and sells.
- New Purchases: CBST,
- Added Positions: CEPH, JNJ, ONXX,
- Reduced Positions: MRK,
- Sold Out: AGN, GILD, MJN,
This is the sector weightings of his portfolio:
| Technology | 1.2% |
| Financials | 0.1% |
| Consumer Services | 6.7% |
| Health Care | 54.4% |
| Consumer Goods | 0.1% |
| Industrials | 1.4% |
These are the top 5 holdings of Edward Owens
- ScheringPlough Corp. (SGP) - 52,941,700 shares, 8.22% of the total portfolio
- Forest Laboratories Inc. (FRX) - 30,133,000 shares, 4.88% of the total portfolio
- McKesson Corp. (MCK) - 11,489,900 shares, 3.76% of the total portfolio
- AstraZeneca PLC (AZN) - 14,881,500 shares, 3.67% of the total portfolio
- Abbott Laboratories (ABT) - 13,300,000 shares, 3.62% of the total portfolio
Added: Cephalon Inc. (CEPH)
Edward Owens added to his holdings in Cephalon Inc. by 37.46%. His purchase prices were between $53.29 and $59.95, with an estimated average price of $56.81. The impact to his portfolio due to this purchase was 0.24%. His holdings were 2,752,000 shares as of 09/30/2009.Cephalon is an international biopharmaceutical company focused on thediscovery development and marketing of products to treat sleep disordersneurological disorders cancer and pain. In addition to an active research and development program they market products in the United States and various countries in Europe. Cephalon Inc. has a market cap of $4.07 billion; its shares were traded at around $54.58 with a P/E ratio of 9.38 and P/S ratio of 2.06. Cephalon Inc. had an annual average earning growth of 10.1% over the past 5 years.
Added: Johnson & Johnson (JNJ)
Edward Owens added to his holdings in Johnson & Johnson by 75%. His purchase prices were between $55.97 and $61.79, with an estimated average price of $59.99. The impact to his portfolio due to this purchase was 0.2%. His holdings were 1,400,000 shares as of 09/30/2009.Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $162.73 billion; its shares were traded at around $59.05 with a P/E ratio of 12.98 and P/S ratio of 2.55. The dividend yield of Johnson & Johnson stocks is 3.32%. Johnson & Johnson had an annual average earning growth of 12.5% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.
Added: Onyx Pharmaceuticals Inc. (ONXX)
Edward Owens added to his holdings in Onyx Pharmaceuticals Inc. by 32.94%. His purchase prices were between $27.23 and $36.55, with an estimated average price of $31.75. The impact to his portfolio due to this purchase was 0.03%. His holdings were 807,200 shares as of 09/30/2009.Onyx Pharmaceuticals Inc is developing innovative products for the treatment of cancer. Onyx Pharmaceuticals Inc. has a market cap of $1.63 billion; its shares were traded at around $26.6 with and P/S ratio of 8.37. Onyx Pharmaceuticals Inc. had an annual average earning growth of 1.3% over the past 5 years.
New Purchase: Cubist Pharmaceuticals Inc. (CBST)
Edward Owens initiated holdings in Cubist Pharmaceuticals Inc.. His purchase prices were between $16.4 and $21.97, with an estimated average price of $19.65. The impact to his portfolio due to this purchase was 0.04%. His holdings were 383,528 shares as of 09/30/2009.Cubist Pharmaceuticals Inc. is a biopharmaceutical company focused on the research development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S. Cubist markets CUBICIN the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington MA. Cubist Pharmaceuticals Inc. has a market cap of $978.56 million; its shares were traded at around $16.94 with a P/E ratio of 10.46 and P/S ratio of 2.26.
Reduced: Merck & Co. Inc. (MRK)
Edward Owens reduced to his holdings in Merck & Co. Inc. by 51.2%. His sale prices were between $26.45 and $32.95, with an estimated average price of $30.39. The impact to his portfolio due to this sale was -0.96%. Edward Owens still held 10,771,200 shares as of 09/30/2009.Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $65.23 billion; its shares were traded at around $30.93 with a P/E ratio of 9.26 and P/S ratio of 2.73. The dividend yield of Merck & Co. Inc. stocks is 4.91%.
Sold Out: Mead Johnson Nutriti (MJN)
Edward Owens sold out his holdings in Mead Johnson Nutriti. His sale prices were between $32.51 and $43.35, with an estimated average price of $37.8.Mead Johnson Nutrition Company is a pediatric nutrition company. It manufactures distributes and sells infant formulas and other nutritional products worldwide primarily under the `Enfa` family of brands. The Company's Enfa family of brands including Enfamil infant formula is a global brand franchise in pediatric nutrition. The company's products include routine and specialty infant formulas children's milks and milk modifiers pediatric vitamins dietary supplements for pregnant and breastfeeding mothers and products for metabolic disorders. It also launched Nutramigen AA an amino acid infant formula for infants with severe protein allergies. The company a subsidiary of Bristol-Myers Squibb Company and headquartered in Evansville Indiana offers its products in North America Europe Asia and Latin America. Mead Johnson Nutriti has a market cap of $3.23 billion; its shares were traded at around $42.04 with a P/E ratio of 20.11 and P/S ratio of 1.12. The dividend yield of Mead Johnson Nutriti stocks is 1.9%.
Sold Out: Gilead Sciences Inc. (GILD)
Edward Owens sold out his holdings in Gilead Sciences Inc.. His sale prices were between $44.24 and $49.81, with an estimated average price of $46.4.Gilead Sciences Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases including viral infections fungal infections and bacterial infections and a specialized focus on cancer. They have expertise in liposomal drug delivery technology a technology that the company uses to develop drugsthat are safer easier for patients to tolerate and more effective. Gilead Sciences Inc. has a market cap of $38.48 billion; its shares were traded at around $42.55 with a P/E ratio of 16.24 and P/S ratio of 7.21. Gilead Sciences Inc. had an annual average earning growth of 53.9% over the past 5 years.
Sold Out: Allergan Inc. (AGN)
Edward Owens sold out his holdings in Allergan Inc.. His sale prices were between $45.36 and $58.18, with an estimated average price of $53.39.Allergan Inc. is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical ophthalmic surgical device over-the-counter contact lens care movement disorder and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care neurotoxins intraocular lenses and other ophthalmic surgical products and contact lens care products. Allergan Inc. has a market cap of $17.1 billion; its shares were traded at around $56.25 with a P/E ratio of 20.38 and P/S ratio of 3.88. The dividend yield of Allergan Inc. stocks is 0.36%.
Rate This Article: |
  |